Skip to content
value.today
Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc.

Total raised
$52 M
1 round on record
Latest round
$52 M
Feb 2014
First round on record
Feb 2014
Today
Went public
See the company page

Aurinia Pharmaceuticals Inc. is listed today as Aurinia Pharmaceuticals Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Aurinia Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2014$52 MNo. 1$50 to $250 million

Aurinia Pharmaceuticals Inc.: Raise no. 1, Feb 2014

Investors in this round

22 investors had bought by the notice of Feb 28, 2014: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$52 M of $52 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$3,494,982
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Alberta, Canada

People named in the notice

  • Dennis M. Bourgeault · Executive Officer
  • Michael M. Martin · Executive Officer, Director
  • Richard M. Glickman · Executive Officer, Director
  • Stephen W. Zaruby · Executive Officer, Director
  • Benjamin M. Rovinski · Director
  • Chris M. Kim · Director
  • Daniel M. Park · Director
  • Donald M. Wyatt · Director
  • Kurt von M. Emster · Director
  • Peter M. Wijngaard · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Canaccord Genuity Inc. (CRD 1020) · New York, New YorkSold in no state named, and outside the US
  • Leerink Partners LLC (CRD 39011) · Boston, MassachusettsSold in CA, CT, MA, MD, NC, NJ, NY

Signed by Stephen W. Zaruby, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 28, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Aurinia Pharmaceuticals Inc., its revenue in fiscal 2025 came from these product and service lines: License, collaboration and royalty revenue $11.71 million (4%).

    Annual report (SEC XBRL) · Dec 2025

  • Aurinia Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2014).

    SEC Form D · Feb 2014

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2014

Products and services#

No products or services of Aurinia Pharmaceuticals Inc. are on record.

Investors#

No investor of Aurinia Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 22 investors.

Largest shareholders today

Institutions holding Aurinia Pharmaceuticals Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Aurinia Pharmaceuticals Inc.
NameRoleNamed in
Dennis M. BourgeaultExecutive officerFeb 2014
Michael M. MartinExecutive officerFeb 2014
Richard M. GlickmanExecutive officerFeb 2014
Stephen W. ZarubyExecutive officerFeb 2014
Benjamin M. RovinskiDirectorFeb 2014
Chris M. KimDirectorFeb 2014
Daniel M. ParkDirectorFeb 2014
Donald M. WyattDirectorFeb 2014
Kurt von M. EmsterDirectorFeb 2014
Michael M. MartinDirectorFeb 2014
Peter M. WijngaardDirectorFeb 2014
Richard M. GlickmanDirectorFeb 2014
Stephen W. ZarubyDirectorFeb 2014

Went public since 2018. Its SEC number is that of a company listed on a stock exchange.